Renal oncocytoma is a benign kidney tumor accounting for approximately 3-7% of all renal epithelial neoplasms. It originates from the distal collecting duct (intercalated cells) epithelium. Histologically composed of cells with abundant eosinophilic granular cytoplasm due to dense intracellular mitochondrial accumulation. Typically presents between ages 50-70 with a male-to-female ratio of 2:1. The classic imaging finding is a central stellate scar, although this is present in only approximately 33% of cases and more common in larger tumors. The most important clinical challenge of oncocytoma is its inability to be reliably distinguished from chromophobe renal cell carcinoma (RCC) on imaging alone, often necessitating surgical resection. Small oncocytomas (<4 cm) typically demonstrate homogeneous enhancement, while larger tumors are characterized by central scar and heterogeneous enhancement. A spoke-wheel pattern of arterial enhancement has been classically described but is not pathognomonic. Absence of segmental enhancement inversion (SEI) may be supportive in differentiation from chromophobe RCC. Multiple oncocytomas and oncocytomatosis associated with Birt-Hogg-Dubé syndrome are rare. Management includes active surveillance or partial nephrectomy; there is no metastatic potential.
Age Range
40-80
Peak Age
65
Gender
Male predominant
Prevalence
Uncommon
Renal oncocytoma originates from intercalated cells of the distal nephron (specifically type A intercalated cells). The most distinguishing feature of tumor cells is the excessive accumulation of mitochondria within the cytoplasm. This mitochondrial hyperplasia develops as a compensatory response due to defective mitochondrial respiratory chain (particularly complex I deficiency). Mitochondrial DNA mutations (especially in MT-ND5, MT-CYB genes) and chromosome 1p deletions (or Y chromosome loss) play a role in pathogenesis. Dense mitochondrial accumulation produces the eosinophilic granular cytoplasm appearance on histology. The vascular architecture of the tumor typically demonstrates an organized pattern radiating from center to periphery (spoke-wheel pattern); this is the basis of the classically described 'spoke-wheel' enhancement pattern on angiography. The central stellate scar represents fibrovascular stroma and non-necrotic connective tissue accumulation at the tumor center — this differs from the necrotic central area seen in malignant tumors. Unlike renal cell carcinomas, oncocytoma does not harbor VHL gene mutations and the HIF-VEGF pathway is not activated; therefore neoangiogenesis intensity is lower and the enhancement pattern differs from clear cell RCC. In cases arising from Birt-Hogg-Dubé syndrome (FLCN gene mutation), bilateral and multiple oncocytomas (oncocytomatosis) may be seen.
Fibrovascular scar structure with star-shaped branching pattern in the tumor center. Fibrous tissue that enhances on delayed phase, appears hypointense on T2, and does not enhance in the arterial phase. Present in only approximately 33% of cases and more common in larger tumors (>3 cm). Oncocytomas with central scar are more easily recognized; in the absence of scar, differential diagnosis is much more challenging. The non-necrotic nature of the scar (viable fibrous tissue) and delayed enhancement distinguishes it from central necrosis in malignant tumors.
Spoke-wheel pattern of enhancement in arterial (corticomedullary) phase, radiating from center to periphery. Organized vascular architecture demonstrates radial spread from center outward. Small tumors (<4 cm) show homogeneous moderate enhancement, while larger tumors demonstrate heterogeneous enhancement due to central scar. Enhancement intensity is generally lower than clear cell RCC (typically <150 HU in arterial phase) but close to or slightly above renal cortex. Tumor margins are smooth and well-defined; invasive growth pattern is not expected.
Report Sentence
Well-defined solid renal mass demonstrating spoke-wheel pattern of enhancement radiating from center to periphery in arterial phase, suggesting renal oncocytoma as the leading diagnosis.
On non-contrast CT, homogeneous solid mass isodense or slightly hyperdense to renal cortex. Attenuation values typically range between 30-45 HU. Calcification, macroscopic fat, and hemorrhage are generally absent. The central scar area may show low density but can be inconspicuous on non-contrast phase. Foci of necrosis are characteristically absent — this is an important differentiating feature from malignant renal masses. Tumor margins are smooth and well-defined; there is no perinephric fat invasion.
Report Sentence
Homogeneous solid renal mass isodense to renal cortex on non-contrast CT with smooth margins; no calcification or necrosis identified.
Homogeneous and persistent enhancement is observed in nephrographic phase — the prominent washout pattern seen in clear cell RCC is not expected in oncocytoma. Tumor density in nephrographic phase remains close to or slightly below renal parenchyma. Enhancement is not markedly greater than renal cortex (typically 70-100% of renal cortex level). In larger tumors, the central scar area remains low density in nephrographic phase or may show mild delayed enhancement. Segmental enhancement inversion (SEI) — where specific segments demonstrate reversed enhancement pattern compared to arterial phase in chromophobe RCC — is not observed in oncocytoma.
Report Sentence
The mass maintains homogeneous enhancement in nephrographic phase without significant washout pattern; no segmental enhancement inversion (SEI) identified.
Delayed enhancement of the central stellate scar area may be observed in delayed phase (5-15 minutes). The scar is a fibrovascular structure that remains low density in arterial and nephrographic phases but enhances slowly in the delayed phase. This delayed enhancement pattern is similar to the central scar behavior in FNH. Scar enhancement can be seen in the delayed phase in approximately 50-70% of cases (among cases where scar is present). The scar demonstrates an irregular star-shaped branching pattern with radial extensions toward the tumor periphery.
Report Sentence
Central stellate scar structure with delayed enhancement is identified within the mass; this finding is compatible with renal oncocytoma.
Central stellate scar demonstrates hypointense signal on T2-weighted images. The scar area is predominantly fibrous tissue and appears dark on T2 due to low water content. The solid portion of the tumor shows mildly hyperintense or isointense signal on T2. Central scar hypointensity is an important MR finding of oncocytoma and is seen in larger tumors (33-50%). Necrotic areas are typically absent; therefore T2 hyperintense fluid collections are not expected. The tumor shows homogeneous signal characteristics — the signal heterogeneity from necrosis/hemorrhage frequently seen in clear cell RCC is not prominent in oncocytoma.
Report Sentence
Hypointense stellate scar structure is identified centrally within the mass on T2-weighted images; no evidence of necrosis or hemorrhage — compatible with renal oncocytoma.
On T1-weighted images, oncocytoma generally demonstrates isointense or mildly hypointense signal relative to renal cortex. Homogeneous signal characteristics are prominent in small tumors (<4 cm). In larger tumors, the central scar area appears hypointense on T1. Hemorrhagic component is rare; if present, it manifests as T1 hyperintense focus, but this is an atypical finding. Intracellular lipid accumulation is not expected in oncocytoma — no signal drop on opposed-phase sequence; this is an important distinction from clear cell RCC.
Report Sentence
The mass demonstrates isointense signal to renal cortex on T1-weighted images; no signal drop on opposed-phase sequence — intracellular lipid accumulation is not considered.
Oncocytoma demonstrates mild diffusion restriction on diffusion-weighted imaging (DWI). ADC (apparent diffusion coefficient) values are generally moderate (typically 1.0-1.8 × 10⁻³ mm²/s), falling between clear cell RCC and chromophobe RCC. Marked diffusion restriction (very low ADC) is not expected — this is more prominent in papillary RCC and chromophobe RCC. DWI alone cannot reliably distinguish oncocytoma from malignant renal masses, but ADC values tend to fall within a specific range. The central scar area shows low signal on DWI (due to low cellularity).
Report Sentence
The mass demonstrates mild diffusion restriction on DWI with moderate ADC values — no marked restriction identified.
On B-mode ultrasonography, oncocytoma is generally visualized as a homogeneous, isoechoic or mildly hyperechoic, well-defined solid mass. Small tumors (<3 cm) may be indistinguishable from renal parenchyma. In the presence of central scar, a central hypoechoic or anechoic area may be seen, but detection on ultrasound is difficult. Cystic component and calcification are typically absent. The tumor is round or oval shaped and may demonstrate an exophytic growth pattern. Ultrasonography cannot reliably distinguish oncocytoma from other solid renal masses; its diagnostic value is limited.
Report Sentence
Isoechoic/mildly hyperechoic, homogeneous, well-defined solid renal mass identified on ultrasound; no cystic component or calcification detected.
On color Doppler ultrasound, oncocytoma may demonstrate a spoke-wheel vascularity pattern radiating from center to periphery. The feeding artery enters from the center of the mass and branches radially toward the periphery. This pattern is the Doppler correlate of the angiographic spoke-wheel finding. However, this finding is not seen in all cases and is difficult to detect in small tumors. Peripheral vascularity or disorganized vascular pattern suggests malignant tumors. Doppler spectral analysis may show low resistive index (RI <0.7) — reflecting the low vascular resistance benign nature of the tumor.
Report Sentence
Spoke-wheel vascularity pattern radiating from center to periphery is identified within the mass on color Doppler; low resistive index (RI) is noted.
Criteria
Homogeneous solid mass, smooth margins, central stellate scar (in larger tumors), spoke-wheel enhancement, no necrosis or hemorrhage, <4 cm typically homogeneous enhancement
Distinct Features
Most commonly encountered form. Diagnosis is easier in the presence of central scar, but scar is found in only approximately 50% of large tumors and 33% of all cases. In small tumors (<4 cm), central scar is usually absent and they demonstrate homogeneous enhancement.
Criteria
Size >7 cm, prominent central scar (more common in larger tumors), heterogeneous enhancement, may have exophytic growth pattern, thin capsule-like structure
Distinct Features
High risk of confusion with malignant tumors (especially RCC) due to large size. Central scar is usually prominent and enhances on delayed phase. May show heterogeneous enhancement but necrotic foci are absent. No perinephric invasion, renal vein thrombosis, or lymphadenopathy — these features are critical in excluding malignancy. Surgical resection is frequently required because definitive diagnosis cannot be made on imaging.
Criteria
Bilateral, multiple oncocytomas, FLCN gene mutation, Birt-Hogg-Dubé syndrome (cutaneous fibrofolliculomas, pulmonary cysts, spontaneous pneumothorax), diffuse oncocytic renal parenchymal infiltration may be present
Distinct Features
A rare condition evaluated in the context of hereditary syndrome. When bilateral multiple renal masses are detected, Birt-Hogg-Dubé syndrome should be considered and genetic testing recommended. Additionally, hybrid oncocytic/chromophobe tumors may be seen in this syndrome — these tumors carry features of both oncocytoma and chromophobe RCC. Nephron-sparing surgery (partial nephrectomy) is preferred; bilateral nephrectomy should be avoided. Pulmonary cysts on chest CT and fibrofolliculomas on dermatological examination should be investigated.
Criteria
Oncocytoma demonstrating hemorrhagic or cystic changes, heterogeneous enhancement, T1 hyperintense areas (hemorrhage), cystic components, irregular margins may be present
Distinct Features
A rare presentation that significantly complicates diagnosis. Hemorrhagic or cystic changes make differentiation from malignant tumors (especially clear cell RCC) virtually impossible. Due to these atypical findings, surgical resection is inevitable and diagnosis can only be made on pathological examination. Perinephric hemorrhage (tumor rupture) may be a rare complication. In cases with cystic changes, Bosniak classification and differentiation from cystic RCC is necessary.
Distinguishing Feature
Chromophobe RCC is the most important differential diagnosis of oncocytoma and reliable differentiation on imaging is often impossible. Chromophobe RCC may demonstrate segmental enhancement inversion (SEI) — segments that enhance intensely in arterial phase show reversed pattern in nephrographic phase; SEI is absent in oncocytoma. Chromophobe RCC may show lower ADC values (more prominent diffusion restriction). Both tumors show homogeneous enhancement; however, rapid growth, capsular invasion, and size >7 cm in chromophobe RCC favor malignancy. Definitive differentiation usually requires biopsy or resection.
Distinguishing Feature
Clear cell RCC demonstrates markedly different enhancement dynamics from oncocytoma. Clear cell RCC shows very intense hypervascular enhancement in arterial phase (typically >150 HU, markedly exceeding renal cortex) with rapid washout in nephrographic phase. In oncocytoma, enhancement is less intense and washout is not prominent. Clear cell RCC shows signal drop on opposed-phase MRI due to intracellular lipid; this drop is not expected in oncocytoma. Clear cell RCC demonstrates necrosis, hemorrhage, and cystic degeneration; oncocytoma is generally homogeneous. Renal vein/IVC thrombus is a spread pattern specific to clear cell RCC and is not seen in oncocytoma.
Distinguishing Feature
Fat-poor angiomyolipoma (AML) may present as a small solid mass with homogeneous enhancement similar to oncocytoma. In fat-poor AML, T2 signal intensity is markedly low (homogeneous hypointense) — in oncocytoma, T2 signal is moderate or mildly hyperintense. On chemical shift MRI, fat-poor AML may contain a small amount of microscopic fat and show minimal signal drop; there is no signal drop in oncocytoma. Fat-poor AML is typically <4 cm and more common in females. On DWI, fat-poor AML shows very low ADC values (marked diffusion restriction); ADC values are higher in oncocytoma.
Distinguishing Feature
Papillary RCC demonstrates a markedly different enhancement pattern from oncocytoma. Papillary RCC is hypovascular and shows low enhancement in arterial phase (markedly lower than renal cortex); slow, progressive enhancement is observed in nephrographic and delayed phases. In oncocytoma, there is moderate-to-high enhancement in arterial phase. T2 signal in papillary RCC is markedly low (lowest T2 signal among all renal masses); in oncocytoma, T2 is moderate or mildly hyperintense. Intratumoral hemorrhage in papillary RCC can create T1 hyperintensity; hemorrhage is rare in oncocytoma. On DWI, papillary RCC shows low ADC values.
Urgency
routineManagement
surveillanceBiopsy
NeededFollow-up
6-monthRenal oncocytoma is a benign tumor with no metastatic potential. However, the primary clinical challenge is the inability to reliably distinguish it from chromophobe RCC on imaging. Therefore, clinical management strategy includes: (1) Percutaneous renal biopsy — increasingly preferred for small renal masses (<4 cm); if oncocytoma is diagnosed, active surveillance can be planned. However, oncocytoma-chromophobe RCC distinction is not always reliable on biopsy (overlapping histological features). (2) Active surveillance — preferred for small (<3-4 cm), stable masses and patients with high surgical risk; periodic CT/MRI follow-up at 3-6 month intervals. (3) Partial nephrectomy — for definitive diagnosis or growing masses; nephron-sparing approach is preferred. (4) Radical nephrectomy — for large tumors (>7 cm) or cases where partial nephrectomy is technically not feasible. Birt-Hogg-Dubé syndrome evaluation: when bilateral/multiple oncocytomas are detected, FLCN gene testing, chest CT (pulmonary cysts), and dermatological examination (fibrofolliculomas) are recommended.
While oncocytoma is benign, surgical excision (partial nephrectomy) is generally performed because it cannot be radiologically differentiated from chromophobe RCC. Percutaneous biopsy is increasingly used in oncocytoma diagnosis and may offer the option of active surveillance.